PMID- 12559498
OWN - NLM
STAT- MEDLINE
DCOM- 20030402
LR  - 20190724
IS  - 0022-510X (Print)
IS  - 0022-510X (Linking)
VI  - 206
IP  - 2
DP  - 2003 Feb 15
TI  - The role of intravenous immunoglobulin in the treatment of multiple sclerosis.
PG  - 123-30
AB  - Intravenous immunoglobulin (IVIG) has several effects on the immune system that 
      could have a beneficial influence on disease processes in multiple sclerosis 
      (MS). Owing to its anti-inflammatory properties, IVIG may be beneficial in the 
      treatment of acute relapses and in prevention of new relapses. By promoting 
      remyelination, IVIG could have a beneficial effect on disability and disease 
      progression. Four double-blind trials in relapsing-remitting MS have demonstrated 
      that IVIG reduces the relapse rate and the number of gadolinium enhancing 
      lesions, and in this respect seems comparable to established therapies in 
      relapsing-remitting MS, i.e. interferon-beta and glatiramer acetate. The doses of 
      IVIG that have been used for treatment in relapsing-remitting have varied 
      10-fold, and the ideal dosage of IVIG for treating MS still needs to be 
      determined. Three studies have been performed to assess the effect of IVIG on 
      chronic visual impairment or established motor symptoms in MS. None of these 
      trials could confirm that established symptoms in MS can be reversed by IVIG. In 
      secondary progressive MS, a large randomized placebo-controlled trial has 
      recently shown that IVIG is without beneficial effects in this phase of the 
      disease. In conclusion, IVIG is a valuable alternative for treatment of 
      relapsing-remitting MS in patients who do not tolerate or are unwilling to take 
      the approved injectable medications, but additional studies are needed to 
      establish the role of IVIG in the management of multiple sclerosis.
FAU - Sorensen, Per Soelberg
AU  - Sorensen PS
AD  - MS Research Unit, Department of Neurology, Copenhagen University Hospital, 
      Rigshospitalet, DK-2100 Copenhagen, Denmark.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - J Neurol Sci
JT  - Journal of the neurological sciences
JID - 0375403
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Central Nervous System/immunology/physiopathology
MH  - Disease Progression
MH  - Humans
MH  - Immunoglobulin G/administration & dosage/*therapeutic use
MH  - Immunoglobulins, Intravenous/classification/immunology/*therapeutic use
MH  - Multiple Sclerosis/pathology/*therapy
RF  - 61
EDAT- 2003/02/01 04:00
MHDA- 2003/04/04 05:00
CRDT- 2003/02/01 04:00
PHST- 2003/02/01 04:00 [pubmed]
PHST- 2003/04/04 05:00 [medline]
PHST- 2003/02/01 04:00 [entrez]
AID - S0022510X0200343X [pii]
AID - 10.1016/s0022-510x(02)00343-x [doi]
PST - ppublish
SO  - J Neurol Sci. 2003 Feb 15;206(2):123-30. doi: 10.1016/s0022-510x(02)00343-x.